Progenics Pharmaceuticals to Participate in Investor Conferences
TARRYTOWN, N.Y., March 29, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will present at two upcoming investor conferences in New York City:
-
11th Annual Needham Healthcare Conference
10:40 a.m. ET, Tuesday, April 3
-
19th Annual Future Leaders in the Biotech Industry Conference
2:30 p.m. ET, Friday, April 20
Both presentations will be webcast live and will be archived for 30 days on the Events page of Progenics' website.
About Progenics
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company dedicated to developing innovative medicines to treat disease, with a focus on cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an
exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) subcutaneous injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness. Regulatory approval is pending for use of RELISTOR by patients with chronic, non-cancer pain. Salix and Progenics have announced positive highly statistically significant results from a phase 3 trial of oral methylnaltrexone in chronic, non-cancer pain subjects with opioid-induced constipation.
The Progenics Pharmaceuticals Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9678
Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this release.
(PGNX-G)
Editor's Note:
For more information, please visit www.progenics.com.
CONTACT: Amy Martini
Corporate Affairs
(914) 789-2816
amartini@progenics.com
Source: Progenics Pharmaceuticals Inc.
News Provided by Acquire Media
Print page |
Email page
| 
Download PDF
|
Add to briefcase